Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Assets Average (2022 - 2026)

bioAffinity Technologies has reported Assets Average over the past 5 years, most recently at $9.5 million for Q1 2026.

  • Quarterly Assets Average rose 56.75% to $9.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Mar 2026, up 56.75% year-over-year, with the annual reading at $8.7 million for FY2025, 18.59% up from the prior year.
  • Assets Average was $9.5 million for Q1 2026 at bioAffinity Technologies, down from $11.3 million in the prior quarter.
  • Over five years, Assets Average peaked at $13.1 million in Q4 2022 and troughed at $5.1 million in Q2 2025.
  • The 5-year median for Assets Average is $8.7 million (2023), against an average of $8.7 million.
  • Year-over-year, Assets Average crashed 30.71% in 2024 and then skyrocketed 72.26% in 2025.
  • A 5-year view of Assets Average shows it stood at $13.1 million in 2022, then dropped by 29.85% to $9.2 million in 2023, then fell by 29.03% to $6.5 million in 2024, then soared by 72.26% to $11.3 million in 2025, then dropped by 16.0% to $9.5 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Assets Average are $9.5 million (Q1 2026), $11.3 million (Q4 2025), and $8.1 million (Q3 2025).